CURE.AX vs. NDIA.AX

Last updated Jul 16, 2026

CURE.AX (Global X S&P Biotech ETF) and NDIA.AX (Global X India Nifty 50 ETF) are both exchange-traded funds - CURE.AX is a Health & Biotech Equities fund tracking the S&P Biotechnology Select Industry Index, while NDIA.AX is a Global Equities fund tracking the Global X India Nifty 50 Index. Both are passively managed. Over the past 5 years, CURE.AX returned 5.62%/yr vs 3.53%/yr for NDIA.AX. At a 0.17 correlation, their price movements are largely independent.

Performance

CURE.AX vs. NDIA.AX - Performance Comparison

The chart below illustrates the hypothetical performance of a A$10,000 investment in Global X S&P Biotech ETF (CURE.AX) and Global X India Nifty 50 ETF (NDIA.AX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CURE.AX achieves a 22.66% return, which is significantly higher than NDIA.AX's -16.20% return.

CURE.AX

• 1D: 0.58%
• 1M: 17.05%
• 6M: 20.39%
• YTD: 22.66%
• 1Y: 65.69%
• 3Y*: 21.60%
• 5Y*: 5.62%
• 10Y*: —

NDIA.AX

• 1D: -0.32%
• 1M: -0.09%
• 6M: -14.59%
• YTD: -16.20%
• 1Y: -19.09%
• 3Y*: -0.52%
• 5Y*: 3.53%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CURE.AX vs. NDIA.AX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
CURE.AX Global X S&P Biotech ETF	22.66%	25.25%	8.13%	10.63%	-22.98%	-17.10%	38.31%	7.30%
NDIA.AX Global X India Nifty 50 ETF	-16.20%	-3.68%	13.96%	15.07%	2.37%	24.83%	-0.22%	0.08%

Correlation

The correlation between CURE.AX and NDIA.AX is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.25
Correlation (3Y) Calculated over the trailing 3-year period	0.17
Correlation (5Y) Calculated over the trailing 5-year period	0.19
Correlation (All Time) Calculated using the full available price history since Jun 19, 2019	0.17

Return for Risk

CURE.AX vs. NDIA.AX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CURE.AX

CURE.AX Risk / Return Rank: 90
CURE.AX Sharpe Ratio Rank: 92
CURE.AX Sortino Ratio Rank: 90
CURE.AX Omega Ratio Rank: 87
CURE.AX Calmar Ratio Rank: 95
CURE.AX Martin Ratio Rank: 87

NDIA.AX

NDIA.AX Risk / Return Rank: 1
NDIA.AX Sharpe Ratio Rank: 0
NDIA.AX Sortino Ratio Rank: 1
NDIA.AX Omega Ratio Rank: 1
NDIA.AX Calmar Ratio Rank: 3
NDIA.AX Martin Ratio Rank: 1

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CURE.AX vs. NDIA.AX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Global X S&P Biotech ETF (CURE.AX) and Global X India Nifty 50 ETF (NDIA.AX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	CURE.AX	NDIA.AX	Difference
Sharpe ratio: Return per unit of total volatility	2.62	-1.21	+3.83
Sortino ratio: Return per unit of downside risk	3.46	-1.79	+5.25
Omega ratio: Gain probability vs. loss probability	1.43	0.81	+0.62
Calmar ratio: Return relative to maximum drawdown	5.80	-0.78	+6.58
Martin ratio: Return relative to average drawdown	14.61	-1.44	+16.05

CURE.AX vs. NDIA.AX - Sharpe Ratio Comparison

The current CURE.AX Sharpe Ratio is 2.62, which is higher than the NDIA.AX Sharpe Ratio of -1.21. The chart below compares the historical Sharpe Ratios of CURE.AX and NDIA.AX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

CURE.AX vs. NDIA.AX - Drawdown Comparison

The maximum CURE.AX drawdown since its inception was -59.81%, which is greater than NDIA.AX's maximum drawdown of -33.23%. Use the drawdown chart below to compare losses from any high point for CURE.AX and NDIA.AX.

Drawdown Indicators

	CURE.AX	NDIA.AX	Difference
Max Drawdown Largest peak-to-trough decline	-59.81%	-33.23%	-26.58%
Max Drawdown (1Y) Largest decline over 1 year	-11.68%	-24.49%	+12.81%
Max Drawdown (3Y) Largest decline over 3 years	-28.37%	-26.05%	-2.32%
Max Drawdown (5Y) Largest decline over 5 years	-50.92%	-26.05%	-24.87%
Current Drawdown Current decline from peak	-5.45%	-21.81%	+16.36%
Average Drawdown Average peak-to-trough decline	-27.38%	-6.91%	-20.47%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.66%	13.40%	-8.74%

Volatility

CURE.AX vs. NDIA.AX - Volatility Comparison

Global X S&P Biotech ETF (CURE.AX) has a higher volatility of 9.67% compared to Global X India Nifty 50 ETF (NDIA.AX) at 5.23%. This indicates that CURE.AX's price experiences larger fluctuations and is considered to be riskier than NDIA.AX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CURE.AX	NDIA.AX	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.67%	5.23%	+4.44%
Volatility (6M) Calculated over the trailing 6-month period	21.01%	13.91%	+7.10%
Volatility (1Y) Calculated over the trailing 1-year period	25.95%	15.90%	+10.05%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	30.91%	16.13%	+14.78%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	31.70%	19.38%	+12.32%

Dividends

CURE.AX vs. NDIA.AX - Dividend Comparison

CURE.AX has not paid dividends to shareholders, while NDIA.AX's dividend yield for the trailing twelve months is around 2.14%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019
CURE.AX Global X S&P Biotech ETF	0.00%	0.00%	0.00%	0.00%	0.06%	11.64%	9.47%	2.05%
NDIA.AX Global X India Nifty 50 ETF	2.14%	1.83%	1.04%	1.86%	4.74%	0.11%	0.00%	0.08%

Frequently Asked Questions

Can I hold both CURE.AX and NDIA.AX in my portfolio?

CURE.AX and NDIA.AX have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

What is the main difference between CURE.AX and NDIA.AX?

CURE.AX is categorized as Health & Biotech Equities, while NDIA.AX is Global Equities. CURE.AX tracks S&P Biotechnology Select Industry Index, while NDIA.AX tracks Global X India Nifty 50 Index.